GlassScriptPhysician profile
Nicole M Tyer
NPI 1346400785
$5,761.29
in general payments reported to CMS, 2019-2025
22 companies · $865 in 2025
The $865 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $355 · 2022: $3,060 · 2023: $780 · 2024: $702 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,346.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,667.43 | 2021-2025 | Wegovy |
| Abbvie INC. | $544.93 | 2023-2025 | Ubrelvy, Vraylar, Synthroid |
| Amgen INC. | $250.99 | 2023-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $235.25 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Madrigal Pharmaceuticals | $168.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Edwards Lifesciences Corporation | $106.34 | 2023-2024 | Sapien 3 Ultra Resilia |
| Almatica Pharma LLC | $95.63 | 2023-2024 | Loreev Xr |
| Pfizer INC. | $83.92 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $79.49 | 2024-2025 | |
| Heartflow, INC. | $71.24 | 2023-2025 | Ffrct |
| Exact Sciences Corporation | $67.59 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $61.96 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.61 | 2024-2025 | Jardiance |
| Boston Scientific Corporation | $45.33 | 2023 | Bodyguardian |
| Davol INC. | $42.61 | 2023 | Phasix Mesh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $38.42 | 2024-2025 | Amvuttra |
| Glaxosmithkline, LLC. | $32.86 | 2024 | Shingrix, Arexvy |
| Kiniksa Pharmaceuticals International, Plc | $29.73 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $21.85 | 2024 | |
| Shield Therapeutics INC | $21.36 | 2023 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $18.29 | 2023 | Seglentis, Livalo |
| Regeneron Healthcare Solutions, INC. | $17.12 | 2024 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Tyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.